NASDAQ$GERN
Geron Corp · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Geron reported financial results and operational highlights.
Geron Corporation reported a net loss of $23.8 million for the fourth quarter of 2020. The company ended the year with $260 million in cash and marketable securities, expected to fund operations until the end of 2022.
- IMerge Phase 3 achieved 65% enrollment, with full enrollment expected in the second half of 2021 and top-line results available from the end of 2022 to the first half of 2023.
- IMpactMF opened for screening and enrollment in December 2020, with event-driven analyses projected for 2024 (interim) and 2025 (final).
- Preparations have begun for the future submission of an NDA for imetelstat in lower risk MDS, with a potential commercial launch in 2024.
- New analyses of IMbark Phase 2 data support overall survival (OS) outcome and disease-modifying potential of imetelstat.
Headline financials
Revenue & EPS history
Geron · Revenue · Quarterly
$50K
Revenue by segment
Geron · $164K total across 1 segment · Q3 2023
- Royalties$164K—100.0%
Forward guidance
Geron provided financial guidance for fiscal year 2021, expecting operating expenses to range from $108 to $112 million and planning to grow to a total of approximately 80 to 85 employees by year-end 2021.
Tailwinds
- Costs for the two ongoing Phase 3 clinical trials.
- Producing validation batches of imetelstat at contract manufacturers to enable future production of imetelstat for clinical and commercial purposes.
- Preparatory activities for NDA and commercial readiness.
- Sufficient cash to fund operations until the end of 2022.
- Majority of new hires will be research and development personnel.
Headwinds
- Operating expense burn expected to range from $108 to $112 million.
- COVID-19 pandemic may cause delays in clinical site openings, patient screening, and enrollment.
- Normalization of clinical site operations remains uncertain and unpredictable.
- Enrollment in IMpactMF is expected to be slower due to competing trials and constrained site personnel resources.
- The fluid and dynamic nature of the pandemic continues to create uncertainty and unpredictability on our clinical trial activities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+4.2%
Avg return
30 days after
42%
27 / 64 earnings
Positive
+35.3%
Q4 2013
Best reaction
-32.1%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.2% | -15.8% | -29.1% | |
| Q4 2025 | -11.3% | -20.5% | -28.2% | |
| Q3 2025 | -4.5% | +0.9% | +13.9% | |
| Q1 2025 | -0.8% | -3.0% | +21.2% | |
| Q4 2024 | -32.1% | -27.8% | -30.4% | |
| Q3 2024 | -0.5% | -7.0% | -8.0% | |
| Q2 2024 | +3.1% | +0.2% | -6.8% | |
| Q1 2024 | -3.7% | -5.1% | -13.0% | |
| Q4 2023 | -3.4% | +0.5% | +59.4% | |
| Q3 2023 | +2.6% | -1.0% | +3.1% | |
| Q2 2023 | -7.5% | -7.5% | -22.5% | |
| Q1 2023 | +9.9% | +6.0% | +27.7% | |
| Q4 2022 | -3.4% | -10.7% | -24.8% | |
| Q3 2022 | -2.3% | +0.9% | +7.0% | |
| Q2 2022 | +8.3% | +2.3% | +22.1% | |
| Q1 2022 | +13.8% | +11.5% | +8.5% | |
| Q4 2021 | +0.9% | -3.7% | +46.3% | |
| Q3 2021 | -9.3% | -8.7% | -21.5% | |
| Q2 2021 | +4.9% | +4.1% | +11.5% | |
| Q1 2021 | +4.5% | +7.5% | +12.8% | |
| Q4 2020 | -6.0% | -3.3% | -19.1% | |
| Q3 2020 | -4.8% | -0.5% | -2.7% | |
| Q2 2020 | -2.3% | -7.0% | +6.4% | |
| Q1 2020 | -1.8% | +0.0% | +17.7% | |
| Q4 2019 | -6.8% | -7.8% | +7.8% | |
| Q3 2019 | +0.7% | +0.0% | +2.0% | |
| Q2 2019 | -3.3% | -0.8% | +16.7% | |
| Q1 2019 | -0.6% | -3.3% | -19.9% | |
| Q4 2018 | +0.7% | +7.7% | +27.3% | |
| Q3 2018 | +9.2% | +7.8% | +5.2% | |
| Q2 2018 | +4.5% | +4.8% | +63.6% | |
| Q1 2018 | -9.9% | -10.9% | -2.1% | |
| Q4 2017 | +24.7% | +43.4% | +10.6% | |
| Q3 2017 | -8.9% | -8.4% | -14.2% | |
| Q2 2017 | -7.1% | -8.4% | -5.8% | |
| Q1 2017 | +0.8% | +11.7% | +4.7% | |
| Q4 2016 | +2.3% | -0.9% | +5.6% | |
| Q3 2016 | +2.7% | +2.2% | +8.6% | |
| Q2 2016 | -0.4% | +0.0% | +1.1% | |
| Q1 2016 | -2.2% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +3.4% | — | — | |
| Q2 2015 | -7.8% | — | — | |
| Q1 2015 | +3.1% | — | — | |
| Q4 2014 | -7.0% | — | — | |
| Q3 2014 | +20.2% | — | — | |
| Q2 2014 | -5.3% | — | — | |
| Q1 2014 | -6.4% | — | — | |
| Q4 2013 | +35.3% | — | — | |
| Q3 2013 | +28.2% | — | — | |
| Q2 2013 | +14.6% | — | — | |
| Q1 2013 | -1.8% | — | — | |
| Q4 2012 | -5.1% | — | — | |
| Q3 2012 | -1.5% | — | — | |
| Q2 2012 | +3.8% | — | — | |
| Q1 2012 | -0.7% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | +4.2% | — | — | |
| Q2 2011 | -15.6% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +1.7% | — | — | |
| Q3 2010 | -4.5% | — | — | |
| Q2 2010 | +26.4% | — | — | |
| Q1 2010 | +3.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro